Patents by Inventor Bernd Puellmann

Bernd Puellmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11981661
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein B, C, L, X, Y, RL and R3 to R5 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Grant
    Filed: September 2, 2021
    Date of Patent: May 14, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Joerg Benz, Uwe Grether, Benoit Hornsperger, Carsten Kroll, Bernd Kuhn, Rainer E. Martin, Fionn O'Hara, Bernd Puellmann, Hans Richter, Martin Ritter
  • Patent number: 11814375
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L1, X, m, n, and R1 to R7 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: November 14, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Joerg Benz, Luca Gobbi, Uwe Grether, Katrin Groebke Zbinden, Benoit Hornsperger, Carsten Kroll, Bernd Kuhn, Rainer E. Martin, Fionn O'Hara, Bernd Puellmann, Hans Richter, Martin Ritter
  • Publication number: 20230257354
    Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R9 and p are as described herein: Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.
    Type: Application
    Filed: March 6, 2023
    Publication date: August 17, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Zhanling CHENG, Christian LERNER, Yongqiang LIU, Matthias NETTEKOVEN, Philippe PFLIEGER, Bernd PUELLMANN, Jianhua WANG, Min WANG, Yongguang WANG, Song YANG, Chengang ZHOU
  • Publication number: 20230203043
    Abstract: The invention provides novel imidazopyrazine derivatives having the general formula (I), or pharmaceutically acceptable salts thereof, wherein X and R3 to R9 are as described herein: Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.
    Type: Application
    Filed: October 28, 2022
    Publication date: June 29, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jean-Baptiste BLANC, Christian LERNER, Matthias NETTEKOVEN, Philippe PFLIEGER, Bernd PUELLMANN, Sébastien SCHMITT, Theodor STOLL, Song YANG, Chengang ZHOU
  • Publication number: 20230017532
    Abstract: Provided are novel imidazopyrazine derivatives having the general formula (I), wherein A and R1 to R11 are as described herein and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and related diseases.
    Type: Application
    Filed: June 16, 2021
    Publication date: January 19, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Zhanling CHENG, Nawaz KHAN, Christian KRAMER, Christian LERNER, Matthias NETTEKOVEN, Philippe PFLIEGER, Bernd PUELLMANN, Sebastien SCHMITT, Theodor STOLL, Jianhua WANG, Song YANG
  • Publication number: 20230012368
    Abstract: Provided are novel imidazopyrazine derivatives having the general formula (I), wherein R1 to R11 are as described herein and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and related diseases.
    Type: Application
    Filed: June 16, 2021
    Publication date: January 12, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jean-Baptiste BLANC, Zhanling CHENG, Xingchun HAN, Nawaz KHAN, Christian KRAMER, Holger KUEHNE, Christian LERNER, Matthias NETTEKOVEN, Philippe PFLIEGER, Bernd PUELLMANN, Sebastien SCHMITT, Theodor STOLL, Jianhua WANG, Yongguang WANG, Song YANG
  • Publication number: 20220396565
    Abstract: Provided are novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R4, m, n, and p are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.
    Type: Application
    Filed: July 20, 2022
    Publication date: December 15, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Zhanling CHENG, Xingchun HAN, Christian KRAMER, Christian LERNER, Yongqiang LIU, Matthias NETTEKOVEN, Philippe PFLIEGER, Bernd PUELLMANN, Jianhua WANG, Lisha WANG, Min WANG, Yongguang WANG, Song YANG, Chengang ZHOU
  • Patent number: 11390604
    Abstract: The disclosure provides novel imidazole pyrazole derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein X1, RA and R3 to R7 are as described herein: Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: July 19, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jean-Baptiste Blanc, Christian Kramer, Christian Lerner, Matthias Nettekoven, Philippe Pflieger, Bernd Puellmann, Thomas Ryckmans, Sébastien Schmitt, Min Wang, Song Yang, Chengang Zhou
  • Publication number: 20220106328
    Abstract: The invention provides new heterocyclic compounds having the general formulae (Ia) and (Ib) wherein A, B, and L are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Application
    Filed: December 16, 2021
    Publication date: April 7, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg BENZ, Luca GOBBI, Uwe GRETHER, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Rainer E. MARTIN, Fionn O`HARA, Bernd PUELLMANN, Hans RICHTER, Martin RITTER
  • Publication number: 20220098176
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein B, C, L, X, Y, RL and R3 to R5 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Application
    Filed: September 2, 2021
    Publication date: March 31, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg BENZ, Uwe GRETHER, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Rainer E. MARTIN, Fionn O'HARA, Bernd PUELLMANN, Hans RICHTER, Martin RITTER
  • Publication number: 20210094943
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L1, X, m, n, and RI to R7 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Application
    Filed: September 10, 2020
    Publication date: April 1, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg BENZ, Luca GOBBI, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Rainer E. MARTIN, Fionn O`HARA, Bernd PUELLMANN, Hans RICHTER, Martin RITTER
  • Publication number: 20210094972
    Abstract: The invention provides new heterocyclic compounds having the general formulae (Ia) and (Ib) wherein A, B, and L are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Application
    Filed: September 22, 2020
    Publication date: April 1, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg BENZ, Luca GOBBI, Uwe GRETHER, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Rainer E. MARTIN, Fionn O`HARA, Bernd PUELLMANN, Hans RICHTER, Martin RITTER
  • Publication number: 20200290998
    Abstract: The disclosure provides novel imidazole pyrazole derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein X1, RA and R3 to R7 are as described herein: Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.
    Type: Application
    Filed: March 6, 2020
    Publication date: September 17, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jean-Baptiste Blanc, Christian Kramer, Christian Lerner, Matthias Nettekoven, Philippe Pflieger, Bernd Puellmann, Thomas Ryckmans, Sébastien Schmitt, Min Wang, Song Yang, Chengang Zhou
  • Publication number: 20160083357
    Abstract: The invention relates to a compound of formula (I) wherein R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: December 4, 2015
    Publication date: March 24, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Uwe Grether, Matthias Nettekoven, Bernd Puellmann, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch
  • Patent number: 9090615
    Abstract: The invention relates to a compound of formula (I) wherein A1, R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: July 28, 2015
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Atsushi Kimbara, Uwe Grether, Matthias Nettekoven, Bernd Puellmann, Mark Rogers-Evans, Tanja Schulz-Gasch
  • Publication number: 20150111886
    Abstract: The invention relates to a compound of formula (I) wherein A1, R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: December 22, 2014
    Publication date: April 23, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Atsushi Kimbara, Uwe Grether, Matthias Nettekoven, Bernd Puellmann, Mark Rogers-Evans, Tanja Schulz-Gasch
  • Patent number: 7691863
    Abstract: The present invention relates to compounds of the formula wherein R1 to R4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB2 receptors.
    Type: Grant
    Filed: September 24, 2007
    Date of Patent: April 6, 2010
    Assignee: Hoffman-La Roche Inc.
    Inventors: Michel Dietz, Sabine Gruener, Paul Hebeisen, Sylvie C. Meyer Reigner, Matthias Nettekoven, Bernd Puellmann, Stephan Roever, Christoph Ullmer
  • Publication number: 20080085905
    Abstract: The present invention relates to compounds of the formula wherein R1 to R4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB2 receptors.
    Type: Application
    Filed: September 24, 2007
    Publication date: April 10, 2008
    Inventors: Michel Dietz, Sabine Gruener, Paul Hebeisen, Sylvie Meyer Reigner, Matthias Nettekoven, Bernd Puellmann, Stephan Roever, Christoph Ullmer
  • Patent number: 6514989
    Abstract: The invention is a compound of formula or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined in the specification. A compound of formula I has a good affinity to the adenosine receptor and can therefore be used for the treatment or protection of diseases mediated by this receptor.
    Type: Grant
    Filed: May 29, 2002
    Date of Patent: February 4, 2003
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Matthias Heinrich Nettekoven, Bernd Puellmann